Themis Bioscience, CEPI initiate Phase 1 study for Lassa Fever vaccine
Category: #health  By Pankaj Singh  Date: 2019-10-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Themis Bioscience, CEPI initiate Phase 1 study for Lassa Fever vaccine

Lassa fever is a severe viral hemorrhagic illness which usually occurs due to human exposure to infected food or household items that are contaminated with feces or urine of Lasa virus infected Mastomys rats. This condition can mainly be seen in areas with heavy rodent population like that in West Africa.

Early precautions and symptomatic treatments can help patients improve their survival chances. However, several pharmaceutical firms are trying to create an effective treatment that is focused on eliminating this disease.

Themis Bioscience, a global biotech company, and The Coalition for Epidemic Preparedness Innovations (CEPI) have recently made one some stride by announcing their first administration to volunteers in Phase 1 clinical study with Themis’ vaccine candidate MV-LASV against Lassa fever.

For the record, MV-LASV is based on Themis’ exclusive measles vector program and solely licensed innovations that were created at Institut Pasteur.

According to reliable sources, the MV-LASV vaccine program is backed through a global collaboration with CEPI that aims at supporting the vaccine’s development until the end of Phase 2, which was created to deliver immunological data and clinical safety.

Speaking on the move, Erich Tauber, MD, CEO, Themis, said that their company’s versatile technology platform and its capability to quickly progress candidates into the clinic has earlier been proven through the production, development and discovery of a Phase 3 vaccine candidate for Chikungunya as well as its newly revealed study for a novel Zika vaccine.

Tauber added that its collaboration with CEPI for Lassa fever justifies its abilities and demonstrates its collective commitment to eradicate those diseases that possess to be a threat to public health globally.

As for Dr. Melanie Saville, Director of Vaccine Development, CEPI, Themis was the first-ever company that it partnered with to create a vaccine against MERS and Lassa fever, two of its significance pathogens.

Saville claims that Lassa fever maintains a severe threat to public health around places like West Africa and this first in-human clinical trial for MV-LASV is a vital step in evaluation an effective vaccine for this disease.
 

Source Credit: https://www.themisbio.com/themis-bioscience-and-cepi-announce-initiation-of-phase-1-clinical-trial-with-lassa-fever-vaccine/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.